Molecular analysis of pediatric brain tumors

被引：16

作者：

Biegel J.A. ^{[1
]}

Pollack I.F. ^{[1
]}

机构：

[1] Division of Human Genetics, Department of Pediatrics, Univ. of Pennsylvania Sch. Medicine, Philadelphia, PA 19104

来源：

Current Oncology Reports | 2004年 / 6卷 / 6期

基金：

美国国家卫生研究院;

关键词：

Astrocytoma; Medulloblastoma; Malignant Glioma; Pilocytic Astrocytoma; Epidermal Growth Factor Receptor Gene;

D O I：

10.1007/s11912-004-0075-5

中图分类号：

学科分类号：

摘要：

The identification of molecular genetic abnormalities in specific types of pediatric brain tumors is beginning to play a role in the stratification of patients into treatment groups. The finding of an INI 1 alteration in an atypical teratoid/ rhabdoid tumor or malignant neoplasm with overlapping histologic features will be required for entry onto diseasespecific protocols within the Children's Oncology Group. Refinement in the classification of medulloblastoma and malignant glioma patients will likely depend on the genetic and signaling pathways that characterize these tumors. Advances in this area will depend on the ability to identify new disease genes, validate prognostic markers, and develop biologically based therapeutic strategies to tailor treatment. Copyright © 2004 by Current Science Inc.

引用

页码：445 / 452

页数：7

共 80 条

[1]

Kleihues P., Cavenee W.K., World Health Organization Classification of Tumours: Pathology and Genetic Tumours of the Nervous System, (2000)

[2]

Packer R.J., Boyett J.M., Zimmerman R.A., Et al., Outcome for children with medulloblastoma treated with radiation and cisplatin CCNU, and vincristine chemotherapy, J. Neurosurg., 81, pp. 690-698, (1994)

[3]

Zeltzer P.M., Boyett J.M., Finlay J.L., Et al., Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study, J. Clin. Oncol., 17, pp. 832-845, (1999)

[4]

Biegel J.A., Rorke L.B., Packer R.J., Et al., Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system, Genes Chromosomes Cancer, 1, pp. 139-147, (1989)

[5]

Biegel J.A., Cytogenetics and molecular genetics of childhood brain tumors, Neuro-Oncol., 1, pp. 139-151, (1999)

[6]

Ellison D., Classifying the medulloblastoma: Insights from morphology and molecular genetics, Neuropathol. Appl. Neurobiol., 28, pp. 257-282, (2002)

[7]

Gilbertson R., Wickramasinghe C., Hernan R., Et al., Clinical and molecular stratification of disease risk in medulloblastoma, Br. J. Cancer, 85, pp. 705-712, (2001)

[8]

Grotzer M.A., Hogarty M.D., Janss A.J., Et al., MYC messenger RNA expression predicts survival outcome in primitive neuroectodermal tumor/medulloblastoma, Clin. Cancer Res., 7, pp. 2425-2433, (2001)

[9]

Lusher M.E., Lindsey J.C., Latif F., Et al., Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development, Cancer Res., 62, pp. 5906-5911, (2002)

[10]

Vos M.D., Martinez A., Elam C., Et al., A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability, Cancer Res., 64, pp. 4244-4250, (2004)

← 1 2 3 4 5 6 7 8 →